Search 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases.

ImmunoINSIGHTS is Oncimmune’s service to the life science industry, built off the company’s proprietary autoantibody profiling technology. The unique combination of Oncimmune’s core technology and understanding of the immune system enables life-science organisations to optimise drug development, leading to more effective, targeted as well as safer treatments for patients.

ImmunoINSIGHTS is underpinned by Oncimmune’s proprietary high throughput immunogenic protein library, one of the largest in the world, allowing for more than 95% of human antigens to be utilised for profiling autoantibodies in patients receiving or about to receive treatment.

With a partnership led approach, Oncimmune is evolving and leveraging its technology with global pharmaceutical and biotechnology companies, early stage start-ups, leading academic groups, and not-for-profit companies.

Oncimmune's immunodiagnostic test, EarlyCDT Lung, can detect and help identify lung cancer on average four years earlier than standard clinical diagnosis. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, EarlyCDT Lung is poised to become an integral component of future lung cancer detection programmes, globally.

Oppilotech develops first-in-class drugs. We believe that target selection is the most important decision we make in drug discovery – a selective high-quality molecule will never become a drug if it is modulating the wrong target.

Oppilotech has developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. The platform is utilized to identify first-in-class drug targets and to develop novel modes of action drugs modulating the identified targets. We undertake both the target selection and develop the drugs against the identified target. We initially focused our modelling efforts on E.coli identifying several first-in-class antibacterial drug targets and generated active chemical matter against them.

The company intends to develop these programmes towards the clinic. We are now expanding into pathways in human cells allowing us to address a wider range of diseases including cancer (e.g. DNA Damage Response) and inflammation.